Cortellini and others investigated 1070 patients with NSCLC, melanoma, RCC, or other advanced-stage cancers who received anti-PD-1/PD-L1 treatments and observed a correlation between high BMI and the development of irAEs that included cutaneous, endocrine, gastrointestinal, liver, among others, adverse events. The gene discussed is PDCD1; the disease is cancer.